Sepsis Diagnostics Market to Hit US$ 1,226.52 million by 2028

High incidence of sepsis due to increasing nosocomial infections and rise in demand for rapid diagnostic tests leading to increasing product launches are the major factors driving the sepsis diagnostics market. Sepsis is a severe medical condition in which the body responds to an infection. It is a life-threatening medical emergency caused due to contamination with bacteria, viruses, or fungi.

The sepsis diagnostics market is projected to reach US$ 1,226.52 million by 2028 from US$ 661.83 million in 2021; it is expected to grow at a CAGR of 9.2% from 2021 to 2028.

Get Sample Copy with Complete TOC and Figures & Graphs @ https://www.theinsightpartners.com/sample/TIPHE100001391/?utm_source=OpenPR&utm_medium=10357

Rising demand for rapid diagnostic tests leading to increasing product launches is expected to accelerate the overall sepsis diagnostics market revenue during the forecast period. However, the lack of skilled professionals limits the market growth.

The sepsis diagnostics market is majorly comprised of top players involving Abbott, F. HOFFMANN-LA ROCHE LTD., Immunexpress Inc., BD, Danaher, Luminex Corporation, THERMO FISHER SCIENTIFIC INC., bioMerieux SA, T2 Biosystems, Inc., and Axis-Shield Diagnostics Ltd.

Technology plays a critical role in healthcare diagnostics as it offers accuracy and saves time and resources and therefore, plays a critical role acting as a future trend in sepsis diagnosis. In sepsis diagnosis process, the identification of causative pathogen is essential in selecting appropriate antibiotic therapy as a part of the treatment. Molecular diagnostics, flow cytometry, microfluidics, immunoassay, biomarkers, and microbiology are majorly used for sepsis diagnostics techniques. Therefore, several companies are investing in point-of-care molecular diagnostics to diagnose bacterial and viral pathogens early and for better patient management. For instance, in October 2020, Immunexpress launched a rapid SeptiCyte, a one-hour molecular diagnostic test for sepsis in Europe on Biocartis' Idylla platform.

Purchase a Copy of this Report: https://www.theinsightpartners.com/buy/TIPHE100001391/?utm_source=OpenPR&utm_medium=10357

About Us:
The Insight Partners is a one-stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Life Science, Technology, Healthcare, Manufacturing, Automotive and Defense, Food Beverages, chemicals etc.

Contact Us:
Call: +1-646-491-9876
Email: sales@theinsightpartners.com

This release was published on openPR.